On January 11, 2021 Targovax ASA, a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, reoported that it has been invited to present at H.C. Wainwright’s BioConnect 2021 Conference, being held virtually on January 11-14, 2021 (Press release, Targovax, JAN 11, 2021, View Source [SID1234573772])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Øystein Soug, CEO of Targovax, will hold a company presentation to conference attendees. The recording will be available on-demand via the H.C. Wainwright conference portal